Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
India
/
Pharmaceuticals & Biotech
Create a narrative
Granules India Community
BSE:532482 Community
1
Narratives
written by author
1
Comments
on narratives written by author
24
Fair Values set
on narratives written by author
Create a narrative
Community Investing Ideas
Granules India
Popular
Undervalued
Overvalued
Granules India
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
New Genome Valley Facility Will Increase Production Capacity To 10 Billion Doses
Key Takeaways Strategic focus on expanding high-growth segments is expected to drive future revenue and enhance earnings stability through improved product approvals. Increased production capacity and quality improvements are set to enhance operational efficiency, supporting sustainable growth and better net margins.
View narrative
₹613.29
FV
28.3% undervalued
intrinsic discount
14.92%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
18
users have followed this narrative
3 days ago
author updated this narrative
Your Valuation for
532482
532482
Granules India
Your Fair Value
₹
Current Price
₹439.65
5.6% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
87b
2015
2018
2021
2024
2025
2027
2030
Revenue ₹87.1b
Earnings ₹9.7b
Advanced
Set Fair Value